Publications

HERIZON-GEA-01: A Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in First-line Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced/metastatic Gastroesophageal Adenocarcinoma (GEA) (ESMO World GI Congress, June 30, 2022)

Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study (American Society of Clinical Oncology, June 6, 2022)

Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study (American Society of Clinical Oncology, June 4, 2022)

Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial (San Antonio Breast Cancer Symposium, December 8, 2021)

Zanidatamab (ZW25) in Combination with Evorpacept (ALX148) in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204) (San Antonio Breast Cancer Symposium, December 8, 2021)

VIDEO: Phase 2 Study of Zanidatamab + Chemotherapy in First-line HER2-expressing Gastroesophageal Adenocarcinoma (GEA) (Presented by: Geoffrey Ku, MD; European Society of Medical Oncology Annual Congress, September 16, 2021)

Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA) (European Society for Medical Oncology Congress, September 16, 2021)

Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action (American Association for Cancer Research Annual Meeting, April 10, 2021)

The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers (American Association for Cancer Research Annual Meeting, April 10, 2021)

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs) (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021)

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021)

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15, 2021)

Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor (# 61O) (European Society for Medical Oncology Asia Congress, November 22, 2019)

Zanidatamab

Zanidatamab Zovodotin

Preclinical